Sep. 1 at 4:49 PM
$NVAX Spinalcord injury market = no available treatments. 0, itโs a desert.
$NGEN has the first pharmacological intervention entering phase 3 (fully funded).
$ABBV just failed their phase 2 trial for SCI. Market is massive. Can become the first treatment available for the indication (perfect buyout opportunity)
$NGEN our phase 2 trail had a 100% success rate. Paralyzed patients recovered significant walking ability, bladder control, sensation, and hand movement/sensation.
Wanted to share an awesome opportunity since the stock is quite cheap after dilution since they secured financial stability for the phase 3. FDA in alignment with
$NGEN on study design after the incredible phase 2 trial success.
Also, only been on the NASDAQ for ~8 months. Really undiscovered biotech. Worth a check out if you are the type to take a peek at another biotech opportunity.
Hereโs a chart of possible revenue opportunities. Only assuming 10% market penetration in the US. Current market cap: ~250mill
๐ฅ
